SELLAS Life Sciences Group

Acquired

SELLAS Life Sciences - Clinical Biopharmaceutical Company

Public · New York, United States · Founded 2012 · $98.5M raised

Headquarters
New York, New York
Employees
1–10
Founded
2012
Business Model
B2B
Total Funding
$98.5M
Last Round
$23.6M Corporate RoundOct 2025
Rounds
5
Type
Public

About

SELLAS Life Sciences is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for a broad range of cancer indications. Its lead product candidate is galinpepimut-S (GPS), a WT1-targeting cancer immunotherapeutic licensed from Memorial Sloan Kettering Cancer Center for hematological malignancies and solid tumors that overexpress the WT1 protein. The company is also developing SLS009, a highly selective CDK9 inhibitor licensed from GenFleet Therapeutics for use outside Greater China. SELLAS partners include Memorial Sloan Kettering, 3D Medicines for Greater China rights to GPS, and GenFleet for the CDK9 program.

Summary

SELLAS Life Sciences Group is a Biotech company based in New York, United States, founded in 2012. It has raised $98.5M in total across 5 rounds, most recently a $23.6M Corporate Round round in Oct 2025.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Corporate RoundCorporate RoundOct 2025
$23.6M

Sign up to see all 6 rounds

Merger through Corporate Round — per-round amounts, valuations, and who invested in each round.

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

SELLAS Life Sciences Group on Indexed.vc
<a href="https://indexed.vc/companies/sellas-life-sciences-group"><img src="https://indexed.vc/api/badge/company/sellas-life-sciences-group" alt="SELLAS Life Sciences Group on Indexed.vc" width="260" height="76" /></a>